A bi-weekly event to present and discuss issues related to developments, applications and commercialization of nanotechnology.

Nanospectra has an approved Investigational Device Exemption for the photo-thermal ablation of solid tumors in recurrent and refractory head and neck cancers, and intends to start a second clinical study in prostate cancer in 2010. In connection with these filings and related work, Nanospectra has conducted extensive studies of the toxicity of gold nanoparticles, including gold-silica/core-shell structures and gold nanorods. The circulation kinetics and toxicity in animal models and, as available, human dosing, will be discussed

Bio: J. Donald Payne

Mr. Payne has been the President and CEO of Nanospectra since the commencement of operations in 2002. As CEO, he has led NBI through the clinical development of its broad-based cancer therapy, including the determination of the US and European regulatory pathways, the design and completion of preclinical studies, regulatory filings with FDA, the engagement of clinical trial sites, and implementation of cGMP processes. Mr. Payne has held progressively senior positions in the life science industry since 1992, holding executive positions with biopharmaceutical, tissue engineering and diagnostic companies

Event Coordinators:
Richard Fink 512-339-5020x130 dfink@appliednanotech.net
Chairman: Dr. Zvi Yaniv

Registration deadline is Friday, November 27 at 5:00 PM Central.

To register, please send an email to Nina Shuvalov NShuvalov@appliednanotech.net with your preferred attendance location.

NOTE: Please note that there will be a change in policy starting with the Fall program. Free Parking will no longer be available at this location. The cost to park in the Frost Building for the Colloquium is estimated at $20. Parking is available at the lot across the street for $7. The sponsors of the Colloquium are sorry for any inconvenience this may cause. Lunches will be provided as usual.